To study tumor microenvironment and tumor immunology in cancer therapeutic resistance and metastatic relapse
The Ren group mainly focuses on elucidating how mesenchymal lineage cells (mesenchymal stem cells and fibroblasts) and immune-regulatory myeloid cells (neutrophils and macrophages) modulate the adaptive immune responses in cancer treatment resistance and metastatic relapse. These studies will fully take advantage of the unique research platform--patient-derived xenograft (PDX) tumors in humanized mouse models at The Jackson Laboratory, with the research goal to develop novel strategies targeting tumor microenvironment to improve the efficacies of conventional cancer therapies and new therapeutics such as immunotherapy.
I am currently engaged in the investigation of the impact of mesenchymal lineage cells and immune-regulatory myeloid cells on adaptive...
Investigating the immune regulatory mechanisms underlying tumor recurrence and metastasis.
The development and providing of the cutting-edge Genome technologies methods for biomedical research.
In a new paper, Jennifer Trowbridge presents the factors and processes that contribute to Hematopoietic stem cells decline...
Trowbridge has been recognized as an outstanding early-career scientist and will receive a $750,000 award.
I am interested in mammary tumors.
Jennifer Sargent and Mark Warner have won a major publication award, highlighting their work with PDX.